ALZN — Alzamend Neuro Inc

Alzamend Neuro Inc (ALZN) is a biotechnology company listed on NASDAQ. It is led by Stephan Jackman, based in 3480 Peachtree Road NE, Atlanta, GA, United States, 30326, with about 4 employees. Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Net income was -$2.7M. ALZN currently screens at market cap $2.4M.

Use this ALZN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALZN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALZN SEC filings page. Lician reads the product cache first so this HTML stays unique to Alzamend Neuro Inc even when a live quote feed is slow.